Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
Alexander Schmitz(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital), Birgitta Lauri(Sunderby sjukhus), Rasmus Froberg Brøndum(Aarhus University), Carsten Helleberg(Herlev Hospital), Bronno van der Holt(Erasmus MC), Lucia Ahlberg(Nordic Myeloma Study Group), Anne Stidsholt Roug(Aalborg University Hospital), Marianne Tang Severinsen(Aalborg University Hospital), Ulf‐Henrik Mellqvist, Anders Waage(St Olav's University Hospital), Davine Hofste op Bruinink(Erasmus MC), Björn Andréasson(NU Hospital Group), Niels Abildgaard(University of Southern Denmark), Hans Erik Johnsen(Herlev Hospital), Nina Gulbrandsen(Oslo University Hospital), Henrik Gregersen(Aalborg University Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Einar Haukås(Stavanger University Hospital), Markus Hansson(Lund University), Vincent van der Velden(Erasmus MC), Ulf Christian Frølund(Roskilde University), Martin Bøgsted(Chr. Hansen (Denmark)), Fredrik Schjesvold(Oslo University Hospital), Pieter Sonneveld(Erasmus MC Cancer Institute), Niels Frost Andersen(Aarhus University Hospital), Peter Gimsing(University of Copenhagen)
Cited by 7
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k